CLK inhibitor T3

CAS No. 2109805-56-1

CLK inhibitor T3( T3 )

Catalog No. M13352 CAS No. 2109805-56-1

CLK inhibitor T3 (T3) is a highly potent, selective, and cell-based stable CDC-like kinase (CLK) inhibitor with 0.67, 15 and 110?nM for CLK1,2 and 3, respectively.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 68 Get Quote
5MG 113 Get Quote
10MG 196 Get Quote
25MG 417 Get Quote
50MG 614 Get Quote
100MG 872 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    CLK inhibitor T3
  • Note
    Research use only, not for human use.
  • Brief Description
    CLK inhibitor T3 (T3) is a highly potent, selective, and cell-based stable CDC-like kinase (CLK) inhibitor with 0.67, 15 and 110?nM for CLK1,2 and 3, respectively.
  • Description
    CLK inhibitor T3 (T3) is a highly potent, selective, and cell-based stable CDC-like kinase (CLK) inhibitor with 0.67, 15 and 110?nM for CLK1,2 and 3, respectively; displays 200-300-fold selectivity over other dual specificity kinases such as DYRK1A and DYRK1B; induces dose-dependent reduction in exon recognition and exhibits an overlapping, but greater effect on transcriptome splicing compared to KH-CB19.
  • In Vitro
    CLK-IN-T3 inhibits DYRK1A (IC50=260 nM) and DYRK1B (IC50=230 nM). CLK-IN-T3 (0.1-10.0 μM; 24 hours) results in mild cell cycle arrest at the G2/M boundary with long-duration (24 h). CLK-IN-T3 (0.5-1.0 μM; 6 hours) decreases phosphorylation of CLK-targeted SR proteins and CLK proteins increase slightly. Cell Cycle Analysis Cell Line:HCT-116 cells.Concentration:0.1, 0.5, 1.0, 5.0, 10.0 μM Incubation Time:24 hours Result:Resulted in mild cell cycle arrest at the G2/M boundary with long-duration (24 h).Western Blot Analysis Cell Line:HCT-116 cells Concentration:0.5, 1.0 μM Incubation Time:6 hours Result:Decreased phosphorylation of CLK-targeted SR proteins and CLK proteins increased slightly.
  • In Vivo
    ——
  • Synonyms
    T3
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    CLK
  • Recptor
    CLK
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    2109805-56-1
  • Formula Weight
    482.588
  • Molecular Formula
    C28H30N6O2
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 4.83 mg/mL (10.01 mM)
  • SMILES
    O=C(NC1=CN2C=C(C3=CC=NC=C3)C=CC2=N1)C4=CC=C(C(C)(C)C(N5CCN(C)CC5)=O)C=C4
  • Chemical Name
    4-(2-methyl-1-(4-methylpiperazin-1-yl)-1-oxopropan-2-yl)-N-(6-(pyridin-4-yl)imidazo[1,2-a]pyridin-2-yl)benzamide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Funnell T, et al. Nat Commun. 2017 Feb 23;8(1):7.
molnova catalog
related products
  • SRI-29329

    A potent, specific CDC-like kinase (CLK) inhibitor with IC50 of 78, 16 and 86 nM for CLK1, 2 and4, respectively; shows no significant activity for CLK3, CDK1, CDK4 and CDK6 (IC50>1,000 nM).

  • CLK2 inhibitor Indaz...

    CLK2 inhibitor Indazole1 is a novel potent, selective inhibitor of CLK2 with IC50 of 2.7 nM.

  • ML167

    A potent, selective CDC-like kinase 4 (CLK4) inhibitor with IC50 of 136 nM, >10-fold selectivity over Clk1, Clk2, Clk3, Dyrk1A/1B.